Defence Therapeutics Inc.
DTC
Rang in aandelen
#29522
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Aandeelprijs
$0.25964327
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$19.68M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-55.64%
Land
CA
Handel Defence Therapeutics Inc. (DTC)
Categorie
Healthcare
Koersgeschiedenis voor Defence Therapeutics Inc. (DTC)
Hoogste slotkoers: $0.27 op 2026-10-01
Laagste slotkoers: $2.50 op 2021-05-01
Laagste slotkoers: $2.50 op 2021-05-01
Koersgeschiedenis van Defence Therapeutics Inc. van 2021 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -27.66% |
| 2025 | 58.71% |
| 2024 | -79.59% |
| 2023 | -28.12% |
| 2022 | -37.44% |
| 2021 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.50 | -4.01% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
